Overview

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.
Phase:
Phase 2
Details
Lead Sponsor:
King's College Hospital NHS Trust
Collaborator:
Advanced Accelerator Applications
Treatments:
Lutetium Lu 177 dotatate